SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (15327)2/19/1998 11:59:00 AM
From: Abuckatatime  Read Replies (1) | Respond to of 32384
 
Fugazi, I saw that article too. Interesting followup, all three reviewers have been given the boot. Or putting it another way, Lanced.



To: Hippieslayer who wrote (15327)2/19/1998 1:55:00 PM
From: Alper H.YUKSEL  Read Replies (2) | Respond to of 32384
 
<< It stated that even though lgnd has top notch scientist and one of the best pipelines around, neither has done squat to increase shareholder value. >>

What should a company do to increase shareholder value over the medium term aside from building the best pipeline around ?

Alper



To: Hippieslayer who wrote (15327)2/19/1998 2:11:00 PM
From: Flagrante Delictu  Respond to of 32384
 
FUGAZI, >> purported Lancet article<< Haven't done squat for shareholders? Chop more liver for the move from $5.50 to the current $14.50. Bernie. P.S. How about linking us to that article, or even better yet, posting it. Bernie.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News